FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115129626> ?p ?o ?g. }

• W3115129626 abstract "Purpose Taxane chemotherapy is commonly used in the management of breast cancer. Hair loss (alopecia) is an expected side effect which may have a significant effect on quality of life. Alopecia is normally temporary but permanent chemotherapy-induced alopecia (pCIA) is increasingly recognised especially following docetaxel chemotherapy. However, the prevalence following docetaxel is not well understood and there is no published literature for paclitaxel chemotherapy. The aim of this study is to investigate the prevalence and patterns of pCIA resulting from both docetaxel and paclitaxel chemotherapy at two tertiary UK cancer centres. Methods In collaboration between Clatterbridge Cancer Centre and The Christie NHS Foundation Trusts, a retrospective survey was conducted for breast cancer patients who had received taxane chemotherapy in the neoadjuvant and adjuvant settings. Patients who had concluded chemotherapy at least a year previously were contacted by post and invited to participate by completing a questionnaire and returning it to their treatment centre. Data collected included the incidence and pattern of pCIA using the Savin pictorial hair loss scale, and the methods used by patients to manage it. Fisher's exact test was used to compare pCIA between the docetaxel and paclitaxel cohorts. Results 383 patients responded to the survey (a 63.3% overall response rate). These comprised 245 patients receiving docetaxel and 138 patients treated with paclitaxel. pCIA was reported by 23.3% of patients receiving docetaxel and 10.1% paclitaxel (p < 0.01). Overall 16.7% of patients in both groups reported the ongoing use of products or appliances such as wigs to camouflage their pCIA. In the docetaxel group, pCIA appeared to be more frequent in post-menopausal women than peri- or pre-menopausal women (37.8%, 12.3% and 19.6% respectively [Chi-square test p < 0.01]). Also in the docetaxel group, there appeared to be a trend for more severe scalp alopecia when the patient also received an aromatase inhibitor (AI) or tamoxifen and this difference was most marked in those who had received both an AI and tamoxifen as components of their treatment regime (p = 0.04). The use of scalp cooling was only recorded in the Christie paclitaxel group (n = 12). Of these 12 patients, 83.3% reported no hair loss. While overall rates of permanent eyebrow, eyelash and nostril hair loss were low, this pattern of hair loss appeared more frequent in the paclitaxel than the docetaxel group 4.3% vs. 1.8% (p = 0.29). Conclusions Both docetaxel and paclitaxel may cause permanent scalp hair loss, but it is significantly more prevalent with docetaxel compared with paclitaxel. Implications for Cancer Survivors Clinicians should counsel patients regarding the risk of permanent alopecia prior to embarking upon taxane chemotherapy and routinely offer scalp cooling if available. More research is required to understand the pathobiology of this important and previously under recognised long-term side effect to enable more active preventive and management approaches." @default.
• W3115129626 created "2021-01-05" @default.
• W3115129626 creator A5012093446 @default.
• W3115129626 creator A5050406487 @default.
• W3115129626 creator A5052896579 @default.
• W3115129626 creator A5053404721 @default.
• W3115129626 creator A5056491116 @default.
• W3115129626 creator A5058451751 @default.
• W3115129626 creator A5071683129 @default.
• W3115129626 creator A5071739641 @default.
• W3115129626 creator A5075051077 @default.
• W3115129626 creator A5075785739 @default.
• W3115129626 creator A5082663457 @default.
• W3115129626 creator A5087731186 @default.
• W3115129626 date "2020-12-22" @default.
• W3115129626 modified "2023-10-15" @default.
• W3115129626 title "Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres" @default.
• W3115129626 cites W1668023273 @default.
• W3115129626 cites W1965483505 @default.
• W3115129626 cites W1971181452 @default.
• W3115129626 cites W1971612996 @default.
• W3115129626 cites W2012927022 @default.
• W3115129626 cites W2026150996 @default.
• W3115129626 cites W2033090658 @default.
• W3115129626 cites W2042138685 @default.
• W3115129626 cites W2045742417 @default.
• W3115129626 cites W2076832634 @default.
• W3115129626 cites W2090105511 @default.
• W3115129626 cites W2101837579 @default.
• W3115129626 cites W2114614279 @default.
• W3115129626 cites W2125060682 @default.
• W3115129626 cites W2165325017 @default.
• W3115129626 cites W2171285233 @default.
• W3115129626 cites W2254058441 @default.
• W3115129626 cites W2260590774 @default.
• W3115129626 cites W2296172845 @default.
• W3115129626 cites W2344563724 @default.
• W3115129626 cites W2507809600 @default.
• W3115129626 cites W2561761320 @default.
• W3115129626 cites W2755101461 @default.
• W3115129626 cites W2789601840 @default.
• W3115129626 cites W2887098300 @default.
• W3115129626 cites W2919198336 @default.
• W3115129626 cites W2963556754 @default.
• W3115129626 cites W4237922021 @default.
• W3115129626 cites W4237971957 @default.
• W3115129626 cites W4293719025 @default.
• W3115129626 doi "https://doi.org/10.1111/ecc.13395" @default.
• W3115129626 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33350015" @default.
• W3115129626 hasPublicationYear "2020" @default.
• W3115129626 type Work @default.
• W3115129626 sameAs 3115129626 @default.
• W3115129626 citedByCount "13" @default.
• W3115129626 countsByYear W31151296262021 @default.
• W3115129626 countsByYear W31151296262022 @default.
• W3115129626 countsByYear W31151296262023 @default.
• W3115129626 crossrefType "journal-article" @default.
• W3115129626 hasAuthorship W3115129626A5012093446 @default.
• W3115129626 hasAuthorship W3115129626A5050406487 @default.
• W3115129626 hasAuthorship W3115129626A5052896579 @default.
• W3115129626 hasAuthorship W3115129626A5053404721 @default.
• W3115129626 hasAuthorship W3115129626A5056491116 @default.
• W3115129626 hasAuthorship W3115129626A5058451751 @default.
• W3115129626 hasAuthorship W3115129626A5071683129 @default.
• W3115129626 hasAuthorship W3115129626A5071739641 @default.
• W3115129626 hasAuthorship W3115129626A5075051077 @default.
• W3115129626 hasAuthorship W3115129626A5075785739 @default.
• W3115129626 hasAuthorship W3115129626A5082663457 @default.
• W3115129626 hasAuthorship W3115129626A5087731186 @default.
• W3115129626 hasBestOaLocation W31151296261 @default.
• W3115129626 hasConcept C121608353 @default.
• W3115129626 hasConcept C126322002 @default.
• W3115129626 hasConcept C143998085 @default.
• W3115129626 hasConcept C16005928 @default.
• W3115129626 hasConcept C167135981 @default.
• W3115129626 hasConcept C2776360568 @default.
• W3115129626 hasConcept C2776694085 @default.
• W3115129626 hasConcept C2777292972 @default.
• W3115129626 hasConcept C2777511904 @default.
• W3115129626 hasConcept C2781190966 @default.
• W3115129626 hasConcept C530470458 @default.
• W3115129626 hasConcept C71924100 @default.
• W3115129626 hasConceptScore W3115129626C121608353 @default.
• W3115129626 hasConceptScore W3115129626C126322002 @default.
• W3115129626 hasConceptScore W3115129626C143998085 @default.
• W3115129626 hasConceptScore W3115129626C16005928 @default.
• W3115129626 hasConceptScore W3115129626C167135981 @default.
• W3115129626 hasConceptScore W3115129626C2776360568 @default.
• W3115129626 hasConceptScore W3115129626C2776694085 @default.
• W3115129626 hasConceptScore W3115129626C2777292972 @default.
• W3115129626 hasConceptScore W3115129626C2777511904 @default.
• W3115129626 hasConceptScore W3115129626C2781190966 @default.
• W3115129626 hasConceptScore W3115129626C530470458 @default.
• W3115129626 hasConceptScore W3115129626C71924100 @default.
• W3115129626 hasIssue "3" @default.
• W3115129626 hasLocation W31151296261 @default.
• W3115129626 hasOpenAccess W3115129626 @default.
• W3115129626 hasPrimaryLocation W31151296261 @default.
• W3115129626 hasRelatedWork W1753522318 @default.
• W3115129626 hasRelatedWork W181195935 @default.

• next